Relacorilant in Combination With Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

• Status: RECRUITING
• Trial end date: 2026-12-01

Summary

This is a Phase 2, single-arm, open-label study to evaluate efficacy and safety of intermittent dosing of relacorilant in combination with nab-paclitaxel and bevacizumab in patients with ovarian cancer.

• Phase: PHASE2

Details

• Lead Sponsor: Corcept Therapeutics
• Treatments: 130-nm albumin-bound paclitaxel; Bevacizumab; relacorilant